A Randomized Controlled Trial: Fuzheng Yangxin Formula for ERAS After CABG (FZYXF-RCT-CABG)
19. august 2026 opdateret af: Peking University Third Hospital
Randomized Controlled Trial of Fuzheng Yangxin Formula in Enhanced Recovery After Coronary Artery Bypass Grafting
This study aims to evaluate the efficacy and safety of Fuzheng Yangxin Formula (FZYXF) in the treatment of qi-yin deficiency syndrome after coronary artery bypass grafting (CABG), formulate an integrated Chinese and Western medicine rehabilitation protocol, develop special proprietary Chinese medicines for postoperative patients, establish a postoperative rehabilitation database, and promote the standardized application and achievement transformation of integrated Chinese and Western medicine therapy in cardiac surgery.
Studieoversigt
Status
Ikke rekrutterer endnu
Intervention / Behandling
Detaljeret beskrivelse
This study adopts a randomized controlled trial design.
A total of 230 patients presenting with qi-yin deficiency syndrome after coronary artery bypass grafting (CABG) will be enrolled and randomly assigned to the Fuzheng Yangxin Formula (FZYXF) experimental group (115 patients) and the control group (115 patients).
The primary outcome is the Seattle Angina Questionnaire (SAQ) score at 7 days after medication.
Secondary outcomes include perioperative safety and follow-up health assessments to comprehensively evaluate the therapeutic efficacy and safety.
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
230
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Gong Yichen, Doctor
- Telefonnummer: +8618611693463
- E-mail: 18611693463@126.com
Undersøgelse Kontakt Backup
- Navn: Peking University 3rd Hospital cardiac surgery
Studiesteder
-
-
-
Beijing, Kina
- Peking University 3rd hospital
-
Kontakt:
- Gong Yichen, Doctor
- Telefonnummer: +8618611693463
- E-mail: 18611693463@126.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
-Patients who have undergone coronary artery bypass grafting (CABG) and present with postoperative qi-yin deficiency syndrome.
Exclusion Criteria:
- Patients with hypersensitivity to any components of Fuzheng Yangxin Formula granules.
- Patients with fever or common cold after surgery.
- Patients with severe postoperative liver and kidney dysfunction.
- Patients who receive concurrent valve surgery or other intracardiac operations
- Patients with end-stage malignant tumors
- Patients with uncontrolled infection or bleeding
- Patients with progressive degenerative systemic diseases, such as severe trauma, multiple organ failure and other severe impairment of vital organ function including severely damaged liver function
- Patients with severe heart failure or cardiogenic shock who cannot tolerate treatment.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: FZYX group
Intervention: Fuzheng Yangxin Formula granules combined with routine postoperative management.
The formula consists of Radix Ginseng 20 g, processed Radix Aconiti Lateralis Preparata 10 g (pre-decocted), Radix Astragali 30 g, Radix Ophiopogonis 20 g, Radix Angelicae Sinensis 15 g, Radix Rehmanniae 15 g, Radix Rhodiolae 30 g, Radix Notoginseng powder 6 g (mixed with warm water for oral use).
Participants take the granules orally for 7 consecutive days after CABG.
|
Intervention: Fuzheng Yangxin Formula granules combined with routine postoperative management.
The formula consists of Radix Ginseng 20 g, processed Radix Aconiti Lateralis Preparata 10 g (pre-decocted), Radix Astragali 30 g, Radix Ophiopogonis 20 g, Radix Angelicae Sinensis 15 g, Radix Rehmanniae 15 g, Radix Rhodiolae 30 g, Radix Notoginseng powder 6 g (mixed with warm water for oral use).
Participants take the granules orally for 7 consecutive days after CABG.
|
|
Ingen indgriben: N-FZYX group
Participants receive routine standard postoperative treatment after coronary artery bypass grafting (CABG).
No additional experimental herbal interventions will be provided.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Score of physical activity limitation dimension in the Seattle Angina Questionnaire (SAQ) at 7 days after medication
Tidsramme: 7 days after operation
|
Measured using the Seattle Angina Questionnaire
|
7 days after operation
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Length of Stay
Tidsramme: Perioperative
|
The postoperative length of hospital stay
|
Perioperative
|
|
Follow-up Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Tidsramme: up to 12 months
|
The incidence of MACCE, which includes all-cause mortality, repeat bypass surgery or stenting, acute myocardial infarction, and stroke.
|
up to 12 months
|
|
Seattle Angina Questionnaire (SAQ) Scores
Tidsramme: up to 12 months
|
Evaluation of the patient's health and angina status, including the total score and scores across 5 dimensions: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception.
|
up to 12 months
|
|
Incidence of poor wound healing.
Tidsramme: up to 30 days
|
Assessed by routine postoperative clinical physical examination.
A positive event is defined as the presence of any of the following: local wound dehiscence (splitting open), abnormal wound exudate (purulent or serous drainage), or the need for secondary surgical suturing/re-suturing. Number and percentage of participants with poor wound healing (number of events / total participants in group × 100%).
|
up to 30 days
|
|
Perioperative MACCE
Tidsramme: Perioperative
|
Composite endpoint before discharge, including death, myocardial infarction, stroke, and revascularization
|
Perioperative
|
|
Graft patency
Tidsramme: perioperative
|
graft patency rate (assessed by angiography)，Using the Fitz-Gibbon grading system, grade A and grade B are considered patent.
|
perioperative
|
|
atrial fibrillation incidence
Tidsramme: perioperative
|
Monitor patients for atrial fibrillation during hospitalization; if it occurs, it is considered positive.
|
perioperative
|
|
Renal failure
Tidsramme: Perioperative
|
Patients who develop new-onset renal failure after surgery and require dialysis
|
Perioperative
|
|
reintubation
Tidsramme: Perioperative
|
Reintubation and mechanical ventilation are required during the postoperative hospital stay
|
Perioperative
|
|
length of ICU stay.
Tidsramme: perioperative
|
length of Intensive Care Unit (ICU) stay.
|
perioperative
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
10. august 2026
Primær færdiggørelse (Anslået)
30. november 2027
Studieafslutning (Anslået)
1. december 2028
Datoer for studieregistrering
Først indsendt
4. august 2026
Først indsendt, der opfyldte QC-kriterier
19. august 2026
Først opslået (Faktiske)
24. august 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
24. august 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
19. august 2026
Sidst verificeret
1. juli 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- FZYX RCT of CABG ERAS
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .